The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 27, 2025

Filed:

Apr. 27, 2018
Applicants:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Amgen Inc., Thousand Oaks, CA (US);

Inventors:

Jennifer Lorraine Gansert, Simi Valley, CA (US);

Abraham Antonio Anderson, Sherman Oaks, CA (US);

Kevin Gorski, Novato, CA (US);

Assignees:

MERCK SHARP & DOHME CORP., Rahway, NJ (US);

AMGEN INC., Thousand Oaks, CA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/763 (2015.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 35/763 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 14/70596 (2013.01); C07K 16/2818 (2013.01); G01N 33/5743 (2013.01);
Abstract

Biomarkers useful for identifying a variety of cancers that are responsive to treatment with a combination therapy comprising pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof and talimogene laherparepvec are provided. Methods of treating cancers that are resistant to monotherapy with pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof are provided. Methods of treating a cancer in a subject having a tumor with a low CD8+ density, a low or negative interferon gamma signature, and/or a low or negative PD-L1 status are also provided.


Find Patent Forward Citations

Loading…